Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity

Biochemistry

Volumn 46, Issue 45, 2007, Pages 13019-13030

  Ahn, Kyunghye ^a   Johnson, Douglas S ^a   Fitzgerald, Laura R ^a   Liimatta, Marya ^a   Arendse, Andrea ^a   Stevenson, Tracy ^a   Lund, Eric T ^a   Nugent, Richard A ^b   Nomanbhoy, Tyzoon K ^c   Alexander, Jessica P ^d   Cravatt, Benjamin F ^d  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c ACTIVX BIOSCIENCES INC   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENTS; ANTIDEPRESSANT PHENOTYPES; CENTRAL NERVOUS SYSTEM; FATTY ACID AMIDE HYDROLASE (FAAH);

FATTY ACIDS; LIPIDS; MAMMALS; NEUROLOGY; PHARMACOKINETICS; UREA;

ENZYMES;

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; N PHENYL 4 (QUINOLIN 2 YLMETHYL)PIPERAZINE 1 CARBOXAMIDE; N PHENYL 4 (QUINOLIN 3 YLMETHYL)PIPERIDINE 1 CARBOXAMIDE; PF 622; PF 750; PIPERAZINE; PIPERIDINE; SERINE DEHYDRATASE; UNCLASSIFIED DRUG; UREA;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN TISSUE; MAMMAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS;

AMIDOHYDROLASES; ANILIDES; ANIMALS; BENZAMIDES; BINDING SITES; CARBAMATES; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; PIPERAZINES; PIPERIDINES; SERINE; TIME FACTORS;

MAMMALIA; RODENTIA;

EID: 36048978697     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi701378g     Document Type: Article

References (50)

1. Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., and Gilula, N. B. (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides, Nature 384, 83-87.
2. Giang, D. K., and Cravatt, B. F. (1997) Molecular characterization of human and mouse fatty acid amide hydrolases, Proc. Natl. Acad. Sci. U.S.A. 94, 2238-2242.
3. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., and Mechoulam, R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science 258, 1946-1949.
4. Lambert, D. M., Vandevoorde, S., Jonsson, K. O., and Fowler, C. J. (2002) The palmitoylethanolamide family: a new class of anti-inflammatory agents?, Curr. Med. Chem. 9, 663-674.
5. Cravatt, B. F., Prospero-Garcia, O., Siuzdak, G., Gilula, N. B., Henriksen, S. J., Boger, D. L., and Lerner, R. A. (1995) Chemical characterization of a family of brain lipids that induce sleep, Science 268, 1506-1509.
6. Rodriguez de Fonseca, F., Navarro, M., Gomez, R., Escuredo, L., Nava, F., Fu, J., Murillo-Rodriguez, E., Giuffrida, A., LoVerme, J., Gaetani, S., Kathuria, S., Gall, C., and Piomelli, D. (2001) An anorexic lipid mediator regulated by feeding, Nature 414, 209-212.
7. Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., and Lichtman, A. H. (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase, Proc. Natl. Acad. Sci. U.S.A. 98, 9371-9376.
8. Kathuria, S., Gaetani, S., Fegley, D., Valino, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., La Rana, G., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V., and Piomelli, D. (2003) Modulation of anxiety through blockade of anandamide hydrolysis, Nat. Med. 9, 76-81.
9. Lichtman, A. H., Shelton, C. C., Advani, T., and Cravatt, B. F. (2004) Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia, Pain 109, 319-327.
10. Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., Krey, J. F., Walker, J. M., Holmes, P. V., Crystal, J. D., Duranti, A., Tontini, A., Mor, M., Tarzia, G., and Piomelli, D. (2005) An endocannabinoid mechanism for stress-induced analgesia, Nature 435, 1108-1112.
11. Chang, L., Luo, L., Palmer, J. A., Sutton, S., Wilson, S. J., Barbier, A. J., Breitenbucher, J. G., Chaplan, S. R., and Webb, M. (2006) Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms, Br. J. Pharmacol. 148, 102-113.
12. Jayamanne, A., Greenwood, R., Mitchell, V. A., Aslan, S., Piomelli, D., and Vaughan, C. W. (2006) Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models, Br. J. Pharmacol. 147, 281-288.
13. Russo, R., LoVerme, J., La Rana, G., Compton, T., Parrot, J., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Calignano, A., and Piomelli, D. (2007) The fatty-acid amide hydrolase inhibitor URB597 (cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice, J. Pharmacol. Exp. Ther. 322, 236-242.
14. Gobbi, G., Bambico, F. R., Mangieri, R., Bortolato, M., Campolongo, P., Solinas, M., Cassano, T., Morgese, M. G., Debonnel, G., Duranti, A., Tontini, A., Tarzia, G., Mor, M., Trezza, V., Goldberg, S. R., Cuomo, V., and Piomelli, D. (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis, Proc. Natl. Acad. Sei. U.S.A. 102, 18620-18625.
15. Naiu, P. S., Varvel, S. A., Ahn, K., Cravatt, B. F., Martin, B. R., and Lichtman, A. H. (2006) Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality, Psychopharmacology 192, 61-70.
16. Huitron-Resendiz, S., Sanchez-Alavez, M., Wills, D. N., Cravatt, B. F., and Henriksen, S. J. (2004) Characterization of the sleep-wake patterns in mice lacking fatty acid amide hydrolase, Sleep 27, 857-865.
17. Cravatt, B. F., Saghatelian, A., Hawkins, E. G., Clement, A. B., Bracey, M. H., and Lichtman, A. H. (2004) Functional disassociation of the central and peripheral fatty acid amide signaling systems, Proc. Natl. Acad. Sci. U.S.A. 101, 10821-10826.
18. Holt, S., Comelli, F., Costa, B., and Fowler, C. J. (2005) Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors, Br. J. Pharmacol. 146, 467-476.
19. Chebrou, H., Bigey, F., Arnaud, A., and Galzy, P. (1996) Study of the amidase signature group, Biochim. Biophys. Acta 1298, 285-293.
20. McKinney, M. K., and Cravatt, B. F. (2005) Structure and function of fatty acid amide hydrolase, Annu. Rev. Biochem. 74, 411-432.
21. Patricelli, M. P., Lovato, M. A., and Cravatt, B. F. (1999) Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolases with distinct catalytic properties, Biochemistry 38, 9804-9812.
22. Patterson, J. E., Ollman, I. R., Cravatt, B. F., Boger, D. L., Wong, C. H., and Lerner, R. A. (1996) Inhibition of oleamide hydrolase catalyzed hydrolysis of the endogenous sleep-inducing lipid cis-9-octadecenamide, J. Am. Chem. Soc. 118, 5938-5945.
23. Romero, A., Du, W., Hwang, I., Rayl, T. J., F. Kimball, S., Leung, D., Hoover, H. S., Apodaca, R. L., Breitenbucher, J. G., Cravatt, B. F., and Boger, D. L. (2007) Potent and selective alpha-ketoheterocycle-based inhibitors of the anandamide and oleamide catabolizing enzyme, fatty acid amide hydrolase, J. Med. Chem. 50, 1058-1068.
24. Boger, D. L., Miyauchi, H., Du, W., Hardouin, C., Fecik, R. A., Cheng, H., Hwang, I., Hedrick, M. P., Leung, D., Acevedo, O., Guimaraes, C. R. W., Jorgensen, W. L., and Cravatt, B. F. (2005) Discovery of a potent, selective, and efficacious class of reversible α-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics, J. Med. Chem. 48, 1849-1856.
25. Leung, D., Hardouin, C., Boger, D. L., and Cravatt, B. F. (2003) Discovering potent and selective reversible inhibitors of enzymes in complex proteomes, Nat. Biotechnol. 21, 687-691.
26. Lichtman, A. H., Leung, D., Shelton, C. C., Saghatelian, A., Hardouin, C., Boger, D. L., and Cravatt, B. F. (2004) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity, J. Pharmacol. Exp. Ther. 311, 441-448.
27. Alexander, J. P., and Cravatt, B. F. (2005) Mechanism of carbamate inactivation of FAAH: Implications for the design of covalent inhibitors and in vivo functional probes for enzymes, Chem. Biol. 12, 1179-87.
28. Zhang, D., Saraf, A., Kolasa, T., Bhatia, P., Zheng, G. Z., Patel, M., Lannoye, G. S., Richardson, P., Stewart, A., Rogers, J. C., Brioni, J. D., and Surowy, C. S. (2007) Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets, Neuropharmacology 52, 1095-1105.
29. Patricelli, M. P., Giang, D. K., Stamp, L. M., and Burbaum, J. J. (2001) Direct visualization of serine hydrolase activities in complex proteome using fluorescent active site-directed probes, Proteomics 1, 1067-1071.
30. Apodaca, R., Breitenbucher, J. G., Pattabiraman, K., Seierstad, M., and Xiao, W. (2006) Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase, WO 2006/074025.
31. Patricelli, M. P., Lashuel, H. A., Giang, D. K., Kelly, J. W., and Cravatt, B. F. (1998) Comparative characterization of a wild type and transmembrane domain-deleted fatty acid amide hydrolase: identification of the transmembrane domain as a site for oligomerization, Biochemistry 37, 15177-87.
32. Ahn, K. (2006) Fatty acid amide hydrolase assay, WO 2006/085196.
33. De Bank, P. A., Kendall, D. A., and Alexander, S. P. (2005) A spectrophotometric assay for fatty acid amide hydrolase suitable for high-throughput screening, Biochem. Pharmacol. 69, 1187-93.
34. Shevchenko, A., Wilm, M., Vorm, O., and Mann, M. (1996) Mass spectrometric sequencing of proteins from silver-stained Polyacrylamide gels, Anal. Chem. 68, 850-8.
35. Perkins, D. N., Pappin, D. J. C., Creasy, D. M., and Cottrell, J. S.(1999) Probability-based protein identification by searching sequence databases using mass spectrometry data, Electrophoresis 20, 3551-67.
36. Nomanbhoy, T. K., Rosenblum, J., Aban, A., and Burbaum, J. J. (2003) Inhibitor focusing: direct selection of drug targets from proteomes using activity-based probes, Assay Drug Dev. Technol. 1, 137-146.
37. Jessani, N., Liu, Y., Humphrey, M., and Cravatt, B. F. (2002) Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness, Proc. Natl. Acad. Sci. U.S.A. 99, 10335-10340.
38. Okerberg, E. S., Wu, J., Zhang, B., Samii, B., Blackford, K., Winn, D. T., Shreder, K. R., Burbaum, J. J., and Patricelli, M. P. (2005) High-resolution functional proteomics by active-site peptide profiling, Proc. Natl. Acad. ScL U.S.A. 102, 4996-5001.
39. Patricelli, M. P., Szardenings, A. K., Liyanage, M., Nomanbhoy, T. K., Wu, M., Weissig, H., Aban, A., Chun, D., Tanner, S., and Kozarich, J. W. (2007) Functional interrogation of the kinome using nucleotide acyl phosphates, Biochemistry 46, 350-358.
40. Yates, J. R., III, Eng, J. K., McCormack, A. L., and Schieltz, D. (1995) Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database, Anal. Chem. 67, 1426-1436.
41. Liu, Y., Patricelli, M. P., and Cravatt, B. F. (1999) Activity-based protein profiling: the serine hydrolases, Proc. Natl. Acad. Sci. U.S.A. 96, 14694-14699.
42. Bracey, M. A., Hanson, M. A., Masuda, K. R., Stevens, R. C., and Cravatt, B. F. (2002) Structural adaptation in a membrane enzyme that terminates endocannabinoid signaling, Science 298, 1793-1796.
43. Copeland, R. A. (2000) Enzymes: A practical introduction to structure, mechanism, and data analysis, 2nd ed., pp 318-349, Wiley-VCH Press, New York.
44. Robertson, J. G. (2005) Mechanistic basis of enzyme-targeted drugs, Biochemistry 44, 5561-5571.
45. Alexander, J. P., and Cravatt, B. F. (2006) The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases, J. Am. Chem. Soc. 128, 9699-9704.
46. Greenbaum, D., Baruch, A., Hayrapetian, L., Darula, Z., Burlin-game, A., Medzihradszky, K. F., and Bogyo, M. (2002) Chemical approaches for functionally probing the proteome, Mol. Cell. Proteomics 1, 60-68.
47. Matsumoto, T., Kori, M., Miyazaki, J., and Kiyota, Y. (2006) Preparation of piperidinecarboxamides and piperazinecarboxamides as fatty acid amide hydrolase (FAAH) inhibitors, WO 2006/054652.
48. Patricelli, M. P., and Cravatt, B. F. (1999) Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism, Biochemistry 38, 14125-14130.
49. McKinney, M. K., and Cravatt, B. F. (2003) Evidence for the distinct roles in catalysis for residues of the serine-serine-lysine catalytic triad of fatty acid amide hydrolase, J. Biol. Chem. 278, 37393-37399.
50. Boger, D. L., and Garbaccio, R. M. (1997) Catalysis of the CC-1065 and duocarmycin DNA alkylation reaction: DNA binding induced conformational change in the agent results in activation, Bioorg. Med. Chem. 5, 263-276.